Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Kerstin M. Kampa-Schittenhelm"'
Publikováno v:
Cell Death and Disease, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract ASPP1 (PPP1R13B) belongs to a family of p53-binding proteins and enhances apoptosis by stimulation of p53-transactivation of selected proapoptotic target genes. It is preferentially expressed in hematopoietic stem cells (HSC) and together wi
Externí odkaz:
https://doaj.org/article/245785d349884613ae1bfd8cd977e713
Autor:
Vasileia Tsintari, Bianca Walter, Falko Fend, Mathis Overkamp, Christian Rothermundt, Charles D. Lopez, Marcus M. Schittenhelm, Kerstin M. Kampa-Schittenhelm
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Metastatic soft tissue sarcoma (STS) are a heterogeneous group of malignancies which are not curable with chemotherapy alone. Therefore, understanding the molecular mechanisms of sarcomagenesis and therapy resistance remains a cri
Externí odkaz:
https://doaj.org/article/87ec9c1c8daa4fadaaec5ec99e1319ad
Autor:
Ingmar Rieger, Vasileia Tsintari, Mathis Overkamp, Falko Fend, Charles D. Lopez, Marcus M. Schittenhelm, Kerstin M. Kampa-Schittenhelm
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Alternative splicing is a common physiologic mechanism to generate numerous distinct gene products from one gene locus, which can result in unique gene products with differing important functional outcomes depending on cell context. Aberrant alternat
Externí odkaz:
https://doaj.org/article/cf3251de66a94a6999be4853e84a32b0
Autor:
Marlon Hafner, Alessia Ruiba, Leonie Kampa, Vincent Kälin, Marian Neidert, Konrad Buchauer, Guido Henke, Ludwig Plasswilm, Marcus M. Schittenhelmn, Kerstin M. Kampa-Schittenhelm
Publikováno v:
Cancer Research. 83:2535-2535
GB is the most common, most aggressive primary brain tumor with a deleterious prognosis. Novel approaches to improve therapy are urgently needed. ASPP2 is a tumor suppressor, directly interacting with p53 to induce apoptosis. We recently identified a
Autor:
Vasileia Tsintari, Bianca Walter, Falko Fend, Mathis Overkamp, Christian Rothermundt, Charles D. Lopez, Marcus M. Schittenhelm, Kerstin M. Kampa-Schittenhelm
Publikováno v:
BMC cancer. 22(1)
Background Metastatic soft tissue sarcoma (STS) are a heterogeneous group of malignancies which are not curable with chemotherapy alone. Therefore, understanding the molecular mechanisms of sarcomagenesis and therapy resistance remains a critical cli
Autor:
Bianca Walter, Marcus M Schittenhelm, Kerstin M Kampa-Schittenhelm, Falko Fend, Mihada Bajrami Saipi, Birgit Federmann, Vasileia Tsintari, Charles D. Lopez, Ulrike A. Mau-Holzmann, Figen Akmut, Barbara Illing
Publikováno v:
EBioMedicine. 42:340-351
Background Apoptosis-stimulating Protein of TP53-2 (ASPP2) is a tumor suppressor enhancing TP53-mediated apoptosis via binding to the TP53 core domain. TP53 mutations found in cancers disrupt ASPP2 binding, arguing for an important role of ASPP2 in T
Autor:
Martin Soekler, Falko Fend, Marcus M Schittenhelm, Wichard Vogel, Irina Bonzheim, Kerstin M Kampa-Schittenhelm, Lothar Kanz, Marius Horger
Publikováno v:
Oncotarget
// Kerstin M. Kampa-Schittenhelm 1 , Wichard Vogel 1 , Irina Bonzheim 2 , Falko Fend 2 , Marius Horger 3 , Lothar Kanz 1 , Martin Soekler 1 and Marcus M. Schittenhelm 1 1 Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmo
Autor:
Kerstin M Kampa-Schittenhelm, Julia Frey, Lara A. Haeusser, Marcus M Schittenhelm, Gunnar Blumenstock, Ashly A. Pavlovsky, Barbara Illing
Publikováno v:
Oncotarget. 8:82897-82909
Activating D816 mutations of the class III receptor tyrosine kinase KIT are associated with the majority of patients with systemic mastocytosis (SM), but also core binding factor (CBF) AML, making KIT mutations attractive therapeutic targets for the
Autor:
E. Schleicher, I. Bonzheim, S.T. Dreher, T. Ganief, Marcus M. Schittenhelm, L. Haeusser, M. Bonin, T. Haverkamp, W. Vogel, Barbara Illing, H.J. Bühring, Gunnar Blumenstock, Figen Akmut, Kerstin M Kampa-Schittenhelm, Vasileia Tsintari, Ulrike A. Mau-Holzmann
Publikováno v:
EBioMedicine
EBioMedicine, Vol 54, Iss, Pp-(2020)
EBioMedicine, Vol 54, Iss, Pp-(2020)
Background: Overriding the differentiation blockage in acute myeloid leukemia (AML) is the most successful mode-of-action in leukemia therapy – now curing the vast majority of patients with acute promyelocytic leukemia (APL) using all-trans retinoi
Autor:
John M. Strother, Kerstin M Kampa-Schittenhelm, Matthew R. Kearney, Kendra Todd, Charles D. Lopez, Emerson Y. Chen, Jeff Donovan, Gina M. Vaccaro, Andrea Burt
Publikováno v:
Anticancer research. 39(1)
Background Based on our pre-clinical data, we hypothesized that sequencing chemotherapy with erlotinib would increase the tumor response rate in patients with metastatic colorectal cancer. Patients and methods A phase II trial (planned n=58) using se